PMID- 28680862
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 16
DP  - 2017
TI  - SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study.
PG  - 27
LID - 10.1186/s40200-017-0308-4 [doi]
LID - 27
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease 
      associated with severe microvascular and macrovascular complications. Our aim is 
      to assess the real world effectiveness of SGT" inhibitors in achieving metabolic 
      therapeutic goals. METHODS: A retrospective, observational study. Inclusion 
      criteria for patients were a previous diagnosis of type 2 diabetes mellitus, 
      age > 18 years, patients receiving either dapagliflozin 10 mg and/or 
      canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 
      diabetes mellitus and acute metabolic complications of diabetes. Patients 
      included in the analysis were enrolled in a health plan at least 6 months prior 
      to the index date (baseline period) and in the 6 months following the index date 
      (follow-up period). Achievement of glycated hemoglobin goals were established as 
      <7%. RESULTS: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 
      inhibitors). Mean age for both groups of patients was 57.68 +/- 11.06 years. The 
      dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. 
      Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c 
      goals were met in 56 patients (19.44%) with similar results with dapagliflozin or 
      canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the 
      highest control rate (30.30%) compared to other regimens. Monotherapy was present 
      in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, 
      P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was 
      associated with better control (P < 0.05, 95% CI, [1.10, 3.92]). CONCLUSION: No 
      difference between the drugs was observed. Real-world effectiveness data of SGLT2 
      inhibitors show that the percentage of patients reaching metabolic goals is low. 
      SLGT2 inhibitors were used more frequently as combined therapy.
FAU - Tamez-Perez, Hector Eloy
AU  - Tamez-Perez HE
AD  - Subdireccion de Investigacion, Facultad de Medicina. Universidad Autonoma de 
      Nuevo Leon, Dr. Aguirre Pequeno, Mitras Centro, C.P. 64460 Monterrey, Nuevo Leon 
      Mexico. ISNI: 0000 0001 2203 0321. GRID: grid.411455.0
AD  - Division de Medicina Interna "Modelo Nova", Clinica Nova, Monterrey, Nuevo Leon 
      Mexico.
FAU - Delgadillo-Esteban, Enrique
AU  - Delgadillo-Esteban E
AD  - Subdireccion de Investigacion, Facultad de Medicina. Universidad Autonoma de 
      Nuevo Leon, Dr. Aguirre Pequeno, Mitras Centro, C.P. 64460 Monterrey, Nuevo Leon 
      Mexico. ISNI: 0000 0001 2203 0321. GRID: grid.411455.0
FAU - Soni-Duque, David
AU  - Soni-Duque D
AD  - Division de Medicina Interna "Modelo Nova", Clinica Nova, Monterrey, Nuevo Leon 
      Mexico.
FAU - Hernandez-Coria, Mayra Ivonne
AU  - Hernandez-Coria MI
AD  - Subdireccion de Investigacion, Facultad de Medicina. Universidad Autonoma de 
      Nuevo Leon, Dr. Aguirre Pequeno, Mitras Centro, C.P. 64460 Monterrey, Nuevo Leon 
      Mexico. ISNI: 0000 0001 2203 0321. GRID: grid.411455.0
FAU - Tamez-Pena, Alejandra Lorena
AU  - Tamez-Pena AL
AD  - Subdireccion de Investigacion, Facultad de Medicina. Universidad Autonoma de 
      Nuevo Leon, Dr. Aguirre Pequeno, Mitras Centro, C.P. 64460 Monterrey, Nuevo Leon 
      Mexico. ISNI: 0000 0001 2203 0321. GRID: grid.411455.0
LA  - eng
PT  - Journal Article
DEP - 20170630
PL  - Switzerland
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC5493113
OTO - NOTNLM
OT  - Canagliflozin
OT  - Dapagliflozin
OT  - Diabetes Mellitus, Type 2
OT  - Effectiveness research, comparative
OT  - Hemoglobin A, Glycosylated
EDAT- 2017/07/07 06:00
MHDA- 2017/07/07 06:01
PMCR- 2017/06/30
CRDT- 2017/07/07 06:00
PHST- 2017/04/06 00:00 [received]
PHST- 2017/06/18 00:00 [accepted]
PHST- 2017/07/07 06:00 [entrez]
PHST- 2017/07/07 06:00 [pubmed]
PHST- 2017/07/07 06:01 [medline]
PHST- 2017/06/30 00:00 [pmc-release]
AID - 308 [pii]
AID - 10.1186/s40200-017-0308-4 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2017 Jun 30;16:27. doi: 10.1186/s40200-017-0308-4. 
      eCollection 2017.